![](https://usinfo.roche.com/rs/975-FPO-828/images/whiterocheAndLiatLogos.png?version=0)
![](https://usinfo.roche.com/rs/975-FPO-828/images/pocLPheroImgText2.png?version=0)
Thank you for your interest. Please fill out the form and someone will be in touch shortly.
To stay informed about the cobas® liat total solution and our future assay launches, please fill out the information below, and we will be in touch!
PCR Technology: The cobas® liat system is gold-standard PCR testing made for the point of care.
Multiplex Testing: One swab, multiple results with cobas® liat singleplex and multiplex assays.
Definitive Results: Who needs a second test?** The cobas® liat system provides fast, accurate lab-quality results at the point of care.
*This product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high, moderate or waived complexity tests. This product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, influenza B, and RSV, not for any other viruses or pathogens.
The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
**cobas® SARS-CoV-2 & Influenza A/B assay: If sample results indicate co-infection of SARS-CoV-2 with Influenza A or Influenza B and a positive influenza result would change clinical management, the sample should be re-tested with a second FDA cleared or EUA influenza test. cobas® SARS-CoV-2 assay: A negative result from an asymptomatic individual is presumptive. See package insert for details.
Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46256
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin. © 2024 Roche Diagnostics
MC-US-13823